Astellas Pharma revised its earnings forecast for the fiscal year ending March 2027 upward, while short covering by short sellers also supported the stock's rebound. The stock was up approximately ¥200 from the previous day in morning trading, bringing it close to its record high since listing.
Astellas Pharma, Japan's second-largest pharmaceutical company, rebounded after raising its earnings forecast for the fiscal year ending March 2027. Short covering also supported the market, and upward momentum has strengthened.
The stock effectively reached a new record high since listing for the first time in approximately 7 months, since 8 April, and was up approximately ¥200 from the previous day as of 9:31 a.m. Attention will focus on future trading trends and the details of the earnings results.